Xyzagen Unveils Hendy Street-Created Animation at the CED Conference and Expands Scientific Communication
PITTSBORO, NC – Xyzagen, a boutique pharmacokinetics consultancy and contract research organization (CRO), is redefining how early drug development is delivered, automated, and communicated. From scientific storytelling to AI-powered tools, Xyzagen continues to push the boundaries of innovation in the life sciences sector.
Animation Explainer Videos Premiere at CED
At the CED Conference, Xyzagen premiered its new explainer animation video, developed in collaboration with Hendy Street. The video introduced an animated mascot representing the company’s First-in-Rat® and First-in-Mouse® pharmacokinetics platforms. The animation was praised for its clarity, originality, and ability to distill complex scientific ideas into an engaging, visual narrative.
Explainer videos are increasingly vital in the life sciences space. They help communicate high-level scientific concepts to a broad audience, enhance stakeholder understanding, and streamline early business development conversations. For companies operating in technically complex fields, a well-executed explainer video can serve as both an educational tool and a powerful differentiator.
Hendy Street's Role in Strategic Branding
Beyond animation, Hendy Street collaborated with Xyzagen on a broader creative strategy. Their work included the development of pitch decks, digital media kits, brand visuals, and messaging frameworks that clearly communicate Xyzagen’s scientific value while remaining accessible to non-expert audiences. This partnership reflects Xyzagen’s belief in blending accurate science with effective storytelling.
AI-Powered PK and TK Analysis Bots Now Available
Xyzagen also launched real-time, automated pharmacokinetics (PK) and toxicokinetics (TK) analysis bots. These tools give biotech and pharmaceutical clients instant access to insights that support dose selection, exposure predictions, and study design. By embedding automation into early-stage drug development, Xyzagen reinforces its commitment to Model-Informed Drug Development (MIDD), allowing for faster and more data-driven decision-making.
Learn more about Xyzagen’s MIDD approach at xyzagen.com.
Chris Crean Featured on the "Beyond the Data" Podcast
Xyzagen CEO Christopher Crean was recently featured on the Beyond the Data podcast, where he discussed the company’s strategic focus, the importance of boutique CROs in drug development, and how Xyzagen uniquely integrates regulatory strategy, translational science, and modeling to accelerate drug pipelines.
About Xyzagen
Xyzagen offers end-to-end support across the drug development lifecycle. With in-house bioanalytical labs, a rodent vivarium, and flexible GLP and non-GLP study options, the company delivers expert-level services in both nonclinical and clinical pharmacokinetics. Xyzagen’s boutique model ensures clients work directly with senior scientists, reducing delays and enhancing the quality of study outcomes.
Whether launching a new candidate or preparing for clinical submission, Xyzagen provides the agility and technical depth to move clients from early discovery to regulatory approval with confidence.
